Search

Your search keyword '"Metanephrine urine"' showing total 213 results

Search Constraints

Start Over You searched for: Descriptor "Metanephrine urine" Remove constraint Descriptor: "Metanephrine urine" Topic adrenal gland neoplasms Remove constraint Topic: adrenal gland neoplasms
213 results on '"Metanephrine urine"'

Search Results

1. [Pheochromocytoma. Preoperative approach].

2. Preoperative prediction of metastatic pheochromocytoma and paraganglioma using clinical, genetic, and biochemical markers: A cohort study.

3. Clinical Significance of Pheochromocytoma Size on the Timing and Extent of Surgery.

4. 24-hour urine metanephrine excretion in patients diagnosed with adrenal incidentaloma: impact of commonly used drugs on a clinical decision.

5. [Comparison of the effectiveness of various methods for determining the level of metanephrines in the diagnosis of pheochromocytomas].

6. Biochemical Assessment of Pheochromocytoma and Paraganglioma.

7. Pediatric total fractionated metanephrines: age-related reference intervals in spot urine.

8. Plasma and urinary metanephrine and normetanephrine concentrations using liquid chromatography with tandem mass spectrometry in healthy cats and in a cat with pheochromocytoma.

9. The clinical utility of plasma and urine metanephrines in hypertensive emergency.

10. Dual-Template Magnetic Molecularly Imprinted Polymer for Simultaneous Determination of Spot Urine Metanephrines and 3-Methoxytyramine for the Diagnosis of Pheochromocytomas and Paragangliomas.

11. Verifying Clinically Derived Reference Intervals for Daily Excretion Rates of Fractionated Metanephrines Using Modern Indirect Reference Interval Models.

12. Risk factors for intraoperative complications in pheochromocytomas.

13. Inpatient Measurements of Urine Metanephrines are Indistinguishable from Pheochromocytoma: Retrospective Cohort Study.

14. Properly Collected Plasma Metanephrines Excludes PPGL After False-Positive Screening Tests.

15. Predictors of Hypotension after Adrenalectomy for Pheochromocytoma.

16. Urinary Free Metanephrines for Diagnosis of Pheochromocytoma and Paraganglioma.

17. Hypertensive Heartbreak.

18. False elevations in urinary metanephrines: under-recognised pitfall with 24-hour urinary volume collection.

19. Pheochromocytoma: A three-decade clinical experience in a multicenter study.

20. Random 'spot' urinary metanephrines compared with 24-h-urinary and plasma results in phaeochromocytomas and paragangliomas.

21. Case report of a phantom pheochromocytoma.

22. Biochemistry may be misleading in metachronous MEN2A-associated phaeochromocytoma following unilateral total adrenalectomy.

23. Clinical factors affecting spot urine fractionated metanephrines in patients suspected pheochromocytoma/paraganglioma.

24. Incidental giant cystic pheochromocytoma: a case report and review of the literature.

25. Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?

26. Pheochromocytoma: An approach to diagnosis.

27. Very high rate of false positive biochemical results when screening for pheochromocytoma in a large, undifferentiated population with variable indications for testing.

28. Development and validation of a clinical model to predict intraoperative hemodynamic instability in patients with pheochromocytomas surgery.

29. Correlation between urinary fractionated metanephrines in 24-hour and spot urine samples for evaluating the therapeutic effect of metyrosine: a subanalysis of a multicenter, open-label phase I/II study.

30. Pheochromocytoma: Positive predictive values of mildly elevated urinary fractionated metanephrines in a large cohort of community-dwelling patients.

31. Pheochromocytoma and Pregnancy.

32. Change of skeletal muscle mass in patients with pheochromocytoma.

33. Clonidine suppression testing for pheochromocytoma in neurofibromatosis type 1.

34. Performance of plasma free metanephrines in diagnosis of pheochromocytomas and paragangliomas in the population of Asturias.

35. Electrical Remodeling of Ventricular Repolarization Abnormality after Treatment in Pheochromocytoma: U Wave Finding in a Retrospective Analysis.

36. Differences in the actions of adrenaline and noradrenaline with regard to glucose intolerance in patients with pheochromocytoma.

38. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O -Methylated Catecholamine Metabolites.

39. Endocrine Conditions in Older Adults: Adrenal Tumors.

40. The challenge of improving the diagnostic yield from metanephrine testing in suspected phaeochromocytoma and paraganglioma.

41. [Biological diagnosis of pheochromocytoma: is there an interest in urinary metanephrines measurement over 3 consecutive days?]

42. High specificity of spot urinary free metanephrines in diagnosis and prognosis of pheochromocytomas and paragangliomas by HPLC with electrochemical detection.

43. Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1.

44. Metanephrines for Evaluating Palpitations and Flushing.

45. PENTRAXIN 3 AS A NEW CARDIOVASCULAR MARKER IN ADRENAL ADENOMAS.

46. Abdominal pain and hipertensive crisis as initial manifestation of a malignant pheocromocytoma.

47. Hemorrhagic pheochromocytoma presenting as severe hypertension with myocardial infarction.

48. Different values of urinary fractionated metanephrines after unilateral adrenalectomy for pheochromocytoma according to time intervals after surgery.

49. Symptom-dependent cut-offs of urine metanephrines improve diagnostic accuracy for detecting pheochromocytomas in two separate cohorts, compared to symptom-independent cut-offs.

50. Pheochromocytoma Masked by Mutation in the TH Gene.

Catalog

Books, media, physical & digital resources